Drugs / CI-8993
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04475523 | Sep 2020 → May 2023 | cancer | Curis, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-01-06 | Curis, Inc. | Results Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Relapsed or Refractory Solid Tumors curis.com ↗ |
| 2021-11-09 | Curis, Inc. | Results Curis Announces New Preclinical Data for CI-8993 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting curis.com ↗
The abstract concluded that the study has validated 89 Zr-Df-CI-8993 for specific binding to huVISTA in-vivo. |
| 2020-06-10 | Curis, Inc. | Regulatory Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody curis.com ↗
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CI-8993, the first-in-class monoclonal anti-VISTA antibody. |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CI-8993 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04475523 ↗ |
| Modality | Monoclonal antibody | “CI-8993 is a fully human immunoglobulin (Ig) G1κ monoclonal antibody (mAb) against the VISTA ligand” NCT04475523 ↗ |
| Route | Intravenous | “Patients will be administered CI-8993 intravenously at a planned infusion rate over 2 hours” NCT04475523 ↗ |